NERV
NASDAQ · Biotechnology
Minerva Neurosciences Inc
$6.09
+0.07 (+1.08%)
Financial Highlights (FY 2025)
Revenue
21.71M
Net Income
4.38M
Gross Margin
66.9%
Profit Margin
20.2%
Rev Growth
+1.1%
D/E Ratio
0.50
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 66.9% | 66.9% | 66.9% |
| Operating Margin | 23.4% | 22.1% | 24.7% |
| Profit Margin | 20.2% | 17.5% | 20.4% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 21.71M | 21.78M | 21.76M |
| Gross Profit | 14.53M | 14.57M | 14.56M |
| Operating Income | 5.09M | 4.82M | 5.37M |
| Net Income | 4.38M | 3.81M | 4.44M |
| Gross Margin | 66.9% | 66.9% | 66.9% |
| Operating Margin | 23.4% | 22.1% | 24.7% |
| Profit Margin | 20.2% | 17.5% | 20.4% |
| Rev Growth | +1.1% | -8.2% | +18.1% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 63.21M | 59.57M | 73.18M |
| Total Equity | 126.47M | 118.93M | 120.51M |
| D/E Ratio | 0.50 | 0.50 | 0.61 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 6.15M | 6.17M | 6.37M |
| Free Cash Flow | 3.82M | 4.48M | 4.63M |